<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   &lt;i&gt;HFE&lt;/i&gt; and other hemochromatosis genes
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       <i>
        HFE
       </i>
       and other hemochromatosis genes
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        <i>
         HFE
        </i>
        and other hemochromatosis genes
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clara Camaschella, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Domenico Girelli, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Benjamin A Raby, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert T Means, Jr, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 19, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic reviews the genetics and functions of the
         <em>
          HFE
         </em>
         gene and other genes associated with hereditary hemochromatosis (HH) syndromes, including some of the more challenging clinical questions related to the likelihood of iron overload in individuals with
         <em>
          HFE
         </em>
         variants, the extent and sequence of testing in an individual with iron overload who does not have a common variant in
         <em>
          HFE
         </em>
         , and the role of screening at-risk populations.
        </p>
        <p>
         Separate topics discuss evaluation and management of hereditary hemochromatosis and other causes of iron overload:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         General evaluation of iron overload – (See
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnosis of HH – (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of HH – (See
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening of at risk relatives – (See
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Testing and counseling first-degree relatives'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iron chelation – (See
         <a class="medical medical_review" href="/z/d/html/7146.html" rel="external">
          "Iron chelators: Choice of agent, dosing, and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          <i>
           HFE
          </i>
          GENE FUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Understanding of
         <em>
          HFE
         </em>
         gene function continues to evolve. The following describes some of the major observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <em>
          HFE
         </em>
         gene was identified in 1996 by positional cloning, 20 years after hereditary hemochromatosis (HH) was recognized as a monogenic disorder linked to the major histocompatability complex (MHC) cluster [
         <a href="#rid1">
          1-4
         </a>
         ]. The gene was originally called HLA-H. Later, the name
         <em>
          HFE
         </em>
         was adopted (H for "high" and Fe as the chemical symbol for iron; the H could also stand for "hereditary" or "homeostatic") [
         <a href="#rid5">
          5,6
         </a>
         ]. The original description of the gene also identified the most common
         <em>
          HFE
         </em>
         mutation, which is presumed to represent an ancestral founder mutation that occurred &gt;4000 years ago in Northern Europe [
         <a href="#rid7">
          7,8
         </a>
         ]. (See
         <a class="local">
          'C282Y'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subsequent studies confirmed the high frequency of two
         <em>
          HFE
         </em>
         variants, C282Y (referred to as 845A for the nucleotide sequence) and H63D (referred to as 187G), in diverse populations with European ancestry including individuals from France, Australia, Italy, and Germany [
         <a href="#rid9">
          9-13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Crystal structure and domain analysis of the HFE protein revealed it to be a cell surface protein with three extracellular domains and a similar structure to class I MHC molecules (
         <a class="graphic graphic_figure graphicRef57597" href="/z/d/graphic/57597.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ]. The HFE protein binds to beta-2-microglobulin (β2-microglobulin) on the cell surface, but unlike MHC molecules, it does not bind or "present" small peptides [
         <a href="#rid15">
          15,16
         </a>
         ]. The C282Y mutation interferes with HFE binding to beta-2-microglobulin and prevents membrane localization [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On the surface of cells, HFE interacts with the transferrin receptor 1 (TfR1) [
         <a href="#rid19">
          19,20
         </a>
         ]. HFE and diferric transferrin compete for binding to the same region of TFR1 [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HFE is ubiquitously expressed, but its main function is in hepatocytes where it positively regulates hepcidin. The mechanism is not completely understood, but it has been proposed that HFE may act via a bone morphogenetic protein (BMP) pathway, by stabilizing the BMP type I receptor ALK3 (activin receptor-like kinase 3) on the cell surface to increase hepcidin transcription and reduce serum iron levels [
         <a href="#rid21">
          21
         </a>
         ]. Pathogenic variants in
         <em>
          HFE
         </em>
         such as C282Y produce a protein that can no longer stabilize ALK3 and in turn are unable to activate the BMP pathway. (See
         <a class="local">
          'HFE variants in hereditary hemochromatosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Support for the role of HFE in the liver comes from observations of increased iron uptake in hepatocytes from
         <em>
          HFE
         </em>
         -knockout mice and individuals with
         <em>
          HFE
         </em>
         mutations [
         <a href="#rid22">
          22,23
         </a>
         ]. In a series of 18 individuals with HH who underwent liver transplantation, hepcidin levels were low before transplant and normalized after transplant, presumably due to normal HFE expression in hepatocytes [
         <a href="#rid24">
          24
         </a>
         ]. A mouse model of tissue-specific
         <em>
          HFE
         </em>
         gene deletion in the intestine did not demonstrate an appreciably altered iron balance, suggesting that normal HFE expression in hepatocytes is sufficient to regulate intestinal iron absorption [
         <a href="#rid25">
          25
         </a>
         ]. In contrast, a mouse model of conditional
         <em>
          HFE
         </em>
         gene deletion in hepatocytes resulted in hemochromatosis [
         <a href="#rid26">
          26
         </a>
         ]. Additional details are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance", section on 'Iron sensing and signaling pathway'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepcidin controls iron absorption in the intestine and iron release from macrophages via its binding to ferroportin [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the placenta, the HFE-beta-2-microglobulin-TfR1 complex may facilitate iron transport to the fetus [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence is increasing for a role for HFE in immune function, perhaps via regulation of the T cell repertoire or by negatively regulating antigen presentation [
         <a href="#rid29">
          29
         </a>
         ]. This is only one aspect of multiple intersections between iron metabolism and immunity [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1129981023">
         <span class="h1">
          <i>
           HFE
          </i>
          VARIANTS IN HEREDITARY HEMOCHROMATOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H298273835">
         <span class="h2">
          Overview of genotypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary hemochromatosis (HH) due to pathogenic variants in
         <em>
          HFE
         </em>
         (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F235200&amp;token=87jLzclRwWxNoI%2BQq5Gg78KhG78YiDjbHxzR0TXk8a1EMOt72hOylIiTmlC%2FHa1f&amp;TOPIC_ID=7067" target="_blank">
          MIM 235200
         </a>
         ) is an autosomal recessive disorder; in the vast majority of cases, affected individuals have biallelic
         <em>
          HFE
         </em>
         mutations.
         <em>
          HFE
         </em>
         -related HH has also been referred to as "type 1" HH, although the complex type-numerical HH classification has been supplanted by a more clinically focused HH classification [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         The most common HH genotype is homozygosity for the C282Y variant (C282Y/C282Y). The H63D variant can contribute to a minority of cases in compound heterozygosity with C282Y (C282Y/H63D), generally in combination with other causes of liver disease that contribute to iron overload, such as alcohol, hepatitis C virus (HCV) infection, or nonalcoholic fatty liver disease (NAFLD) [
         <a href="#rid31">
          31,32
         </a>
         ]. Other point mutations or
         <em>
          HFE
         </em>
         gene deletion are less common. (See
         <a class="local">
          'Rare HFE variants'
         </a>
         below.)
        </p>
        <p>
         The distribution of these genotypes within HH populations of individuals with European ancestry is as follows [
         <a href="#rid10">
          10-13,33-35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          C282Y/C282Y
         </strong>
         – 80 to 100 percent.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          C282Y/H63D
         </strong>
         – 2 to 7 percent.
        </p>
        <p>
        </p>
        <p>
         In unselected series of individuals with European ancestry, the prevalence of homozygous
         <em>
          HFE
         </em>
         C282Y is approximately 1 in 150 to 1 in 300 (0.44 percent) [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
         Observation of iron overload in C282Y heterozygotes (C282Y/wildtype) may represent association rather than causation, as the risk of developing HH is similar to the general population. These individuals may have anoth
         <em>
          er HFE
         </em>
         variant, a pathogenic variant in another gene, or iron overload from another cause such as excess alcohol consumption [
         <a href="#rid34">
          34,38-40
         </a>
         ]. In cases of severe iron overload in a C282Y heterozygote, without evident acquired causes of iron overload, disease variants in other genes may be suspected. (See
         <a class="local">
          'Non-HFE hemochromatosis'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload", section on 'Causes of iron overload'
         </a>
         .)
        </p>
        <p>
         The likelihood of developing iron overload with each of the genotypes is discussed below. (See
         <a class="local">
          'Likelihood of developing iron overload'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1634225">
         <span class="h2">
          C282Y
         </span>
         <span class="headingEndMark">
          —
         </span>
         The C282Y variant is the most common finding in individuals with HH. Homozygosity for C282Y is found in approximately 80 to 100 percent of individuals with clinical iron overload from a genetic cause. (See
         <a class="local">
          'Overview of genotypes'
         </a>
         above.)
        </p>
        <p>
         The C282Y variant has a tyrosine instead of a cysteine at position 282 of the HFE protein. This is caused by a point mutation (a guanine to adenine [G to A] transition) at nucleotide 845 of the
         <em>
          HFE
         </em>
         gene [
         <a href="#rid41">
          41
         </a>
         ]. This change disrupts the interaction of the HFE protein with beta-2-microglobulin (β2-microglobulin), which in turn causes HFE to be sequestered in the cytoplasm and prevents it from being transported to the cell surface and carrying out its normal function [
         <a href="#rid41">
          41
         </a>
         ]. Interestingly, b2-microglobulin knockout mice also develop iron overload [
         <a href="#rid15">
          15,16,42
         </a>
         ]. (See
         <a class="local">
          'HFE gene function'
         </a>
         above.)
        </p>
        <p>
         As noted separately, the C282Y variant is especially common in White people of northern European ancestry, with a population frequency of 4 to 7 percent, and heterozygosity for this variant may have been selected for during evolution. The population frequency is lower in other groups including Native Americans, individuals with Hispanic ethnicity, and individuals with African ancestry, and it is extremely rare in people with East Asian ancestry and individuals with Mexican ancestry (&lt;0.1 percent) [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Epidemiology'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Genotype-phenotype correlations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3962281968">
         <span class="h2">
          H63D
         </span>
         <span class="headingEndMark">
          —
         </span>
         The H63D variant is also seen in individuals with HH, although much less commonly than C282Y. Compound heterozygosity (C282Y/H63D) is seen in a few percent of individuals with HH, usually with mild, non-progressive iron overload and in the presence of other contributory factors such as liver disease from excess alcohol intake, HCV infection, or NAFLD; such other factors need to be searched for and corrected whenever possible [
         <a href="#rid31">
          31,32,35,43
         </a>
         ]. (See
         <a class="local">
          'Overview of genotypes'
         </a>
         above.)
        </p>
        <p>
         The H63D variant has a histidine instead of an aspartate at position 63 of the HFE protein, caused by a point mutation (a cytosine to guanine [C to G] transition) at nucleotide 187 of the
         <em>
          HFE
         </em>
         gene [
         <a href="#rid41">
          41
         </a>
         ]. This change appears to reduce the interaction between HFE and TfR1, but it does not abolish HFE localization to the cell surface or interaction with beta-2-microglobulin. (See
         <a class="local">
          'HFE gene function'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Rare
          <i>
           HFE
          </i>
          variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other rare
         <em>
          HFE
         </em>
         variants have been described, especially in individuals with non-northern European ancestry.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Point mutations
         </strong>
         – A study that genotyped a cohort of 206 individuals with HH who did not have the common C282Y/C282Y genotype found "private" variants in
         <em>
          HFE
         </em>
         in 13 unrelated individuals [
         <a href="#rid44">
          44
         </a>
         ]. Some of these were point mutations that created a premature stop codon (Y52*; E168*; L270R*; A271V*; H341L*); others affected the protein sequence (D141Y; K166N), and their causality is less proven. Affected individuals typically had biallelic variants (eg, they were compound heterozygotes for one of these
         <em>
          HFE
         </em>
         mutations along with C282Y).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <em>
          HFE
         </em>
         S65C variant has been reported to be associated with mild iron overload, only when expressed in combination with C282Y [
         <a href="#rid33">
          33
         </a>
         ]. However, this genotype is no longer considered a hemochromatosis susceptibility genotype since it requires other contributory factors to produce even mild iron overload.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gene deletion
         </strong>
         – Homozygous deletion of the
         <em>
          HFE
         </em>
         -containing region of chromosome 6p has also been described in individuals with HH. This genotype is the most common cause of HH in Sardinia, apparently due to a founder effect [
         <a href="#rid45">
          45-48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1725640019">
         <span class="h2">
          Genetic modifiers of
          <i>
           HFE
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         The penetrance of
         <em>
          HFE
         </em>
         C282Y (development of clinical iron overload in homozygous individuals) is likely to be modified by a number of genetic factors, some of which remain to be elucidated [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           BMP2
          </em>
         </strong>
         – Variants in the gene that encodes bone morphogenetic protein 2 (
         <em>
          BMP2
         </em>
         , also called
         <em>
          BMP2A
         </em>
         ) may modify the phenotype of
         <em>
          HFE
         </em>
         C282Y hemochromatosis [
         <a href="#rid49">
          49,51,52
         </a>
         ]. BMP2 is a ligand for BMP receptors and a regulator of hepcidin, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance", section on 'Iron sensing and signaling pathway'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           BMP6
          </em>
         </strong>
         - Heterozygous mutations affecting the
         <em>
          BMP6
         </em>
         propeptide have been associated with inappropriately reduced hepcidin levels and mild iron overload in some but not all populations [
         <a href="#rid53">
          53-55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           GNPAT
          </em>
         </strong>
         – A variant in the
         <em>
          GNPAT
         </em>
         gene is associated with increased iron in individuals who are homozygous for
         <em>
          HFE
         </em>
         C282Y [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           PCSK7
          </em>
         </strong>
         – A variant in
         <em>
          PCSK7
         </em>
         has been reported to lead to liver fibrosis in individuals with
         <em>
          HFE
         </em>
         -associated hemochromatosis [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other iron regulatory genes
         </strong>
         – Variants in the genes for hepcidin (
         <em>
          HAMP
         </em>
         ) or hemojuvelin (
         <em>
          HJV
         </em>
         ) were associated with an increased risk of clinically significant iron overload in individuals with
         <em>
          HFE
         </em>
         mutations [
         <a href="#rid58">
          58-60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polygenic risk scores
         </strong>
         – A 2022 study involving a series of 2890 C282Y homozygous individuals from the United Kingdom Biobank found that polygenic risk scores (PRS) built up with 128 non-
         <em>
          HFE
         </em>
         common variants associated with markers of increased iron significantly increased the clinical penetrance of iron overload (odds ratio [OR] for top 20 percent of PRS versus the bottom 20 percent, 4.90, 95% CI 1.63-14.73), pointing out the complexity of the overall genetic background [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         All such factors may modify other forms of HH, although
         <em>
          HFE
         </em>
         HH is the most common form of HH.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          NON-
          <i>
           HFE
          </i>
          HEMOCHROMATOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of individuals with hereditary hemochromatosis (HH) are homozygous for
         <em>
          HFE
         </em>
         C282Y. (See
         <a class="local">
          'HFE variants in hereditary hemochromatosis'
         </a>
         above.)
        </p>
        <p>
         However, some individuals have pathogenic variants in other genes including
         <em>
          HJV
         </em>
         ,
         <em>
          HAMP
         </em>
         , and
         <em>
          TFR2
         </em>
         . These rare types of HH are collectively called non-HFE hemochromatosis [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         A 2018 systematic review of non-HFE HH cases was used to create a non-HFE HH database [
         <a href="#rid62">
          62
         </a>
         ]. Major findings included a generally younger age at diagnosis for non-HFE HH (in the 20s for
         <em>
          HJV
         </em>
         and
         <em>
          HAMP
         </em>
         variants and in the early 30s for
         <em>
          TRF2
         </em>
         variants, compared with the 40s for
         <em>
          HFE
         </em>
         -related HH), higher serum ferritin levels and transferrin saturation (TSAT) in the non-HFE patients, and greater likelihood of clinical complications in the non-HFE patients, especially cardiac involvement and hypogonadism.
        </p>
        <p>
         The younger age of presentation compared with classical (
         <em>
          HFE
         </em>
         -related) HH has been reported in other studies and has led to the term juvenile hemochromatosis for individuals with disease variants in the
         <em>
          HJV
         </em>
         and
         <em>
          HAMP
         </em>
         genes [
         <a href="#rid35">
          35,63,64
         </a>
         ]. (See
         <a class="local">
          'Juvenile hemochromatosis'
         </a>
         below.)
        </p>
        <p>
         Some of these gene variants and their clinical characteristics and inheritance patterns are summarized in the table (
         <a class="graphic graphic_table graphicRef56329" href="/z/d/graphic/56329.html" rel="external">
          table 1
         </a>
         ). A general discussion of how these genes regulate systemic iron balance is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance"
         </a>
         .)
        </p>
        <p>
         Other genetic disorders are characterized by iron overload in the brain (eg, hereditary aceruloplasminemia, neuroferritinopathy) or high serum ferritin without systemic iron overload; these are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6231.html" rel="external">
          "Bradykinetic movement disorders in children", section on 'Neurodegeneration with brain iron accumulation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload", section on 'Other causes of high ferritin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H297891066">
         <span class="h2">
          Juvenile hemochromatosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Juvenile hemochromatosis refers to HH that presents in childhood, adolescence, or early adulthood (before age 30 years) [
         <a href="#rid65">
          65
         </a>
         ]. This phenotype, formerly called "type 2" HH, is typically associated with variants in the genes for hemojuvelin (
         <em>
          HJV
         </em>
         ) or hepcidin (
         <em>
          HAMP
         </em>
         ). The prevalence is extremely low, and many case reports describe fatal outcomes due to delayed diagnosis and severe organ iron deposition [
         <a href="#rid66">
          66
         </a>
         ]. In several cases, parents were reported to be consanguineous.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Hemojuvelin (
          <i>
           HJV
          </i>
          )
         </span>
         <span class="headingEndMark">
          —
         </span>
         Juvenile HH due to variants in
         <em>
          HJV
         </em>
         (previously called
         <em>
          HFE2
         </em>
         ) (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F602390&amp;token=87jLzclRwWxNoI%2BQq5Gg71mbd2hLGBcDf%2BEsFooc2C0tOC7uU8E7i9FV6ujBwBSG&amp;TOPIC_ID=7067" target="_blank">
          MIM 602390
         </a>
         ) is an autosomal recessive disorder [
         <a href="#rid67">
          67-70
         </a>
         ]. HH due to an
         <em>
          HJV
         </em>
         mutation has been formerly referred to as "type 2A" HH. This form of juvenile HH has been reported in a number of Italian, Greek and Canadian pedigrees (people of French origin from the geographically isolated Saguenay Lac St Jean region), where several different
         <em>
          HJV
         </em>
         variants have been described [
         <a href="#rid68">
          68,71-73
         </a>
         ]. Affected individuals are more likely to present with cardiomyopathy, reduced glucose tolerance, and hypogonadism, rather than severe liver disease [
         <a href="#rid35">
          35,74
         </a>
         ].
         <em>
          HJV
         </em>
         mutations are reported also in middle-aged individuals of Asian ancestry; however, all had severe clinical complications.
        </p>
        <p>
         Hemojuvelin, a glycosylphosphatidylinositol (GPI) anchor-linked protein, appears to be involved in the BMP pathway that upregulates hepcidin, acting as a BMP coreceptor [
         <a href="#rid75">
          75-78
         </a>
         ]. (See
         <a class="local">
          'Hepcidin (HAMP)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4005677869">
         <span class="h3">
          Hepcidin (
          <i>
           HAMP
          </i>
          )
         </span>
         <span class="headingEndMark">
          —
         </span>
         Juvenile HH due to variants in
         <em>
          HAMP
         </em>
         (hepcidin antimicrobial peptide, also called
         <em>
          LEAP1
         </em>
         ) (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F613313&amp;token=87jLzclRwWxNoI%2BQq5Gg78KHguqNprCF9W%2FiHKQrV0YToCwvYQihlSI2%2B3ghW0qV&amp;TOPIC_ID=7067" target="_blank">
          MIM 613313
         </a>
         ) is an autosomal recessive disorder. HH due to a pathogenic variant in
         <em>
          HAMP
         </em>
         was formerly referred to as "type 2B" HH. This form of juvenile HH has been reported in individuals from Italy, Greece, and Portugal, and in individuals from Asia with high degree of consanguinity [
         <a href="#rid79">
          79-82
         </a>
         ].
        </p>
        <p>
         Low levels of hepcidin result in markedly increased intestinal iron absorption and iron release from macrophages, highlighting the essential role for hepcidin in regulating iron balance. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance", section on 'Hepcidin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Transferrin receptor 2 (
          <i>
           TFR2
          </i>
          )
         </span>
         <span class="headingEndMark">
          —
         </span>
         HH due to variants in
         <em>
          TFR2
         </em>
         (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F604250&amp;token=87jLzclRwWxNoI%2BQq5Gg72wvRE7RSsCCEzlBzKG6P0oNYOBVhdZtsT7859AcFrAF&amp;TOPIC_ID=7067" target="_blank">
          MIM 604250
         </a>
         ) is a rare autosomal recessive disorder. HH due to
         <em>
          TFR2
         </em>
         mutations has been also referred to as "type 3" HH. This disorder has been reported in individuals from Italy, France, Spain, Portugal, and Japan [
         <a href="#rid35">
          35,83-87
         </a>
         ]. The clinical phenotype appears to be of intermediate severity between classical and juvenile HH [
         <a href="#rid35">
          35,86-88
         </a>
         ].
        </p>
        <p>
         The function of the TfR2 protein involves binding to diferric transferrin and iron sensing; unlike TfR1, TfR2 does not import iron and has a lower affinity for diferric transferrin. In the liver, TfR2 is involved in hepcidin regulation [
         <a href="#rid89">
          89,90
         </a>
         ]; patients with
         <em>
          TFR2
         </em>
         variants and a mouse model of
         <em>
          TFR2
         </em>
         inactivation show low hepcidin levels [
         <a href="#rid91">
          91
         </a>
         ] and have iron overload [
         <a href="#rid83">
          83,84,86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance", section on 'Transferrin receptor 2'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Ferroportin (
          <i>
           SLC40A1
          </i>
          ;
          <i>
           FPN1
          </i>
          )
         </span>
         <span class="headingEndMark">
          —
         </span>
         HH due to variants in
         <em>
          SLC40A1
         </em>
         (also called
         <em>
          FPN1
         </em>
         ) (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F606069&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FaG4zHR%2FTWQ2TMG5MmmZgWc3Gri6x9yoJM2PT9JRQ81&amp;TOPIC_ID=7067" target="_blank">
          MIM 606069
         </a>
         ) is an extremely rare autosomal dominant disorder. HH due to a pathogenic variant in
         <em>
          SLC40A1
         </em>
         has also been referred to as "type 4" HH or ferroportin disease. This may represent a cause of HH in individuals of African or Chinese ancestry [
         <a href="#rid92">
          92-94
         </a>
         ]. Cases in individuals with European ancestry have also been reported [
         <a href="#rid95">
          95-99
         </a>
         ].
        </p>
        <p>
         There appear to be two different phenotypes [
         <a href="#rid92">
          92
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Macrophage-type
         </strong>
         – Loss-of-function mutations of ferroportin are thought to produce a molecule that either does not traffic appropriately to the cell surface or that has limited ability to export iron (
         <a class="graphic graphic_figure graphicRef138324" href="/z/d/graphic/138324.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This results in excess accumulation of iron in macrophages, with resulting high serum ferritin, normal to reduced transferrin saturation (TSAT), and mild anemia [
         <a href="#rid100">
          100-102
         </a>
         ]. In young females, hypochromic microcytic anemia may develop that is responsive to iron supplementation [
         <a href="#rid35">
          35
         </a>
         ]. This has also been called macrophage-type (M-type) and is now considered the real ferroportin disease, which is no longer included among HH because of the distinct phenotype [
         <a href="#rid31">
          31,92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatic-type (non-classical)
         </strong>
         – Gain-of-function mutations produce a ferroportin protein that is resistant to hepcidin and retains full iron export capability (
         <a class="graphic graphic_figure graphicRef138324" href="/z/d/graphic/138324.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid103">
          103-105
         </a>
         ]. The mutation may affect the binding site for hepcidin (C326) or occurs in its proximity [
         <a href="#rid106">
          106
         </a>
         ]. Iron overload is similar to classic HH [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This results in increased TSAT, high levels of ferritin and hepcidin, and hepatic iron overload, similar to or more severe than classical HH [
         <a href="#rid31">
          31
         </a>
         ]. Liver biopsy has shown increased hepatocyte iron. In ferroportin disease, unlike classical hemochromatosis, the iron is considerably more prominent in Kupffer cells than in hepatocytes, and fibrosis is primarily sinusoidal [
         <a href="#rid35">
          35,97-99,107
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Ferroportin is the iron transport channel mainly expressed in macrophages and hepatocytes and on the basolateral surface of intestinal enterocytes that is blocked by hepcidin. Ferroportin has also been implicated in the transport of other ions such as manganese [
         <a href="#rid108">
          108
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance", section on 'Ferroportin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1785688214">
         <span class="h2">
          <i>
           PIGA
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2022 study identified variants in
         <em>
          PIGA
         </em>
         in three patients with an unusual phenotype resembling the juvenile hemochromatosis phenotype, with the addition of severe neurologic abnormalities (early-onset epilepsy, severe developmental delay, and intellectual disability) [
         <a href="#rid109">
          109
         </a>
         ]. All three were males and were diagnosed during childhood due to neurologic findings; they were also found to have evidence of iron overload and low hepcidin levels.
        </p>
        <p>
         <em>
          PIGA
         </em>
         , located on the X chromosome, encodes the phosphatidylinositol glycan anchor biosynthesis class A protein, the first enzyme in the pathway that adds a glycophosphatidylinositol (GPI) anchor to certain plasma membrane proteins to maintain their cell surface attachment. The hemojuvelin protein is GPI-anchored, suggesting this may be the mechanism by which these
         <em>
          PIGA
         </em>
         variants cause reduction of hepcidin and iron overload. The mechanism of the neurologic findings remains unexplained; however, homologues of hemojuvelin (repulsive guidance molecules [RGMs]) are expressed on normal neuronal cells and are GPI-anchored; low levels of ceruloplasmin, which is also GPI-anchored on glial cells, may contribute.
        </p>
        <p>
         Germline
         <em>
          PIGA
         </em>
         variants are associated with other congenital anomalies (multiple congenital anomalies-hypotonia-seizures syndrome-2 [MCAHS2]). Acquired somatic
         <em>
          PIGA
         </em>
         variants in hematopoietic stem cells are seen in paroxysmal nocturnal hemoglobinuria (PNH); the lack of a GPI anchor causes deficiency of certain complement regulatory proteins on the surface of circulating red blood cells (RBCs), leading to chronic hemolytic anemia. Individuals with germline pathogenic variants in
         <em>
          PIGA
         </em>
         have no biochemical or clinical signs of PNH, likely because the constitutional (germline) variants allow some residual protein function, at variance with the somatic null mutations. (See
         <a class="medical medical_review" href="/z/d/html/7156.html" rel="external">
          "Pathogenesis of paroxysmal nocturnal hemoglobinuria", section on 'PIGA gene mutation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7156.html" rel="external">
          "Pathogenesis of paroxysmal nocturnal hemoglobinuria", section on 'GPI anchor'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3336327609">
         <span class="h1">
          CLINICAL IMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2010709197">
         <span class="h2">
          Likelihood of developing iron overload
         </span>
        </p>
        <p class="headingAnchor" id="H1261877005">
         <span class="h3">
          Role of
          <i>
           HFE
          </i>
          genotype in iron overload and complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          HFE
         </em>
         -related HH is an autosomal recessive disorder with reduced clinical penetrance. Biallelic
         <em>
          HFE
         </em>
         C282Y mutations are necessary for the development of clinical iron overload but not sufficient; the majority of individuals with biallelic
         <em>
          HFE
         </em>
         mutations will not develop clinical iron overload [
         <a href="#rid61">
          61,110
         </a>
         ].
        </p>
        <p>
         The risk of iron overload in
         <em>
          HFE
         </em>
         C282Y homozygotes is variably estimated in unselected populations to be as low as 1 percent in females to as high as 28 percent in males (
         <a class="graphic graphic_table graphicRef126542" href="/z/d/graphic/126542.html" rel="external">
          table 2
         </a>
         ). This means that as high as 72 to 99 percent of individuals with biallelic
         <em>
          HFE
         </em>
         C282Y mutations will
         <strong>
          not
         </strong>
         develop clinical iron overload, especially females and individuals with a negative family history [
         <a href="#rid111">
          111,112
         </a>
         ].
        </p>
        <p>
         Individuals who develop severe iron overload are also at risk for complications such as liver disease (cirrhosis and liver cancer), heart disease (heart failure and arrythmias), endocrine dysfunction, and others. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Manifestations of organ iron overload'
         </a>
         .)
        </p>
        <p>
         In contrast, non-
         <em>
          HFE
         </em>
         hemochromatosis has a much higher clinical prevalence. In cases of severe iron overload in an
         <em>
          HFE
         </em>
         C282Y heterozygote, pathogenic variants in one of the non-
         <em>
          HFE
         </em>
         genes may be suspected. (See
         <a class="local">
          'Non-HFE hemochromatosis'
         </a>
         above.)
        </p>
        <p>
         Heterozygotes for
         <em>
          HFE
         </em>
         C282Y have a similar risk of developing iron overload as the general population. This risk is not zero, as some individuals in the general population have iron overload due to as-yet undiscovered causes, but it is extremely low. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Genotype-phenotype correlations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Heterozygous individuals'
         </a>
         .)
        </p>
        <p>
         The documentation of iron overload depends on the means of assessment (eg, questionnaire versus liver imaging or biopsy). Biochemical evidence of iron overload (increased serum transferrin saturation [TSAT] and ferritin) is more common:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2022 United States biobank study involving 445,521 participants identified 2890 C282Y homozygous individuals (0.7 percent) [
         <a href="#rid113">
          113
         </a>
         ]. Only 12 percent of C282Y homozygous males were diagnosed with hemochromatosis at baseline, and only 33 percent of males and 21 percent of females were diagnosed with hemochromatosis by the end of the 14-year follow-up, at mean ages of 69 and 70 years, respectively [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A population study that identified
         <em>
          HFE
         </em>
         C282Y homozygotes and used patient questionnaires to determine whether they had symptoms of clinical iron overload found that only 1 of 152 (&lt;1 percent) were affected [
         <a href="#rid114">
          114
         </a>
         ]. This study did not include iron studies or other measures of iron overload.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A population study that genotyped 9174 individuals from the Copenhagen City Heart Study identified 23
         <em>
          HFE
         </em>
         C282Y homozygotes [
         <a href="#rid115">
          115
         </a>
         ]. Many had high TSAT and ferritin levels, but none developed clinically overt hemochromatosis over 25 years of follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Hemochromatosis and Iron Overload Screening (HEIRS) study, which screened 101,168 primary care participants for iron overload, 333
         <em>
          HFE
         </em>
         C282Y homozygotes were detected (prevalence, 0.3 percent); of these, 75 (23 percent) had previously been diagnosed with HH [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A population-based study from Australia that performed
         <em>
          HFE
         </em>
         testing on over 30,000 individuals of northern European descent who were between the ages of 40 and 69 years identified 203 C282Y homozygotes (prevalence, 0.65 percent) [
         <a href="#rid111">
          111
         </a>
         ]. During approximately 12 years of follow-up, iron overload and at least one complication (cirrhosis, liver fibrosis, hepatocellular cancer, abnormal liver function tests, and/or classical HH arthropathy) was seen in approximately 28 percent of the C282Y homozygous men and 1 percent of the C282Y homozygous women.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A related study from some of the same authors looked more closely using liver biopsy in 672 asymptomatic individuals who were homozygous for
         <em>
          HFE
         </em>
         C282Y [
         <a href="#rid117">
          117
         </a>
         ]. Hepatic iron overload was identified in 56 percent of males and 35 percent of females, hepatic fibrosis was seen in 18 percent of males and 5 percent of females, and cirrhosis was seen in 6 percent of males and 2 percent of females. More than half of the individuals in this cohort were identified because they had a family member with HH, which could bias the results towards individuals with a greater likelihood of clinically significant iron overload than would be seen in the general population, although results were generally similar regardless of the indication for
         <em>
          HFE
         </em>
         testing.
        </p>
        <p>
        </p>
        <p>
         Further discussion of genetic and acquired factors that can influence disease penetrance are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2897.html" rel="external">
          "Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Penetrance and expressivity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3450643668">
         <span class="h3">
          Additional risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The population data summarized above (see
         <a class="local">
          'Role of HFE genotype in iron overload and complications'
         </a>
         above) can provide a general sense of disease penetrance, but there are a number of potentially useful considerations in estimating the likelihood of iron overload in an individual with biallelic
         <em>
          HFE
         </em>
         mutations [
         <a href="#rid118">
          118-120
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Family history
         </strong>
         – A positive family history of HH-associated iron overload is probably a surrogate for other genetic contributions to increased iron absorption. A study that identified 214
         <em>
          HFE
         </em>
         C282Y homozygous relatives of individuals with HH (mostly siblings) found that up to 43 percent of males and 10 percent of females had a clinical complication of iron overload such as elevated hepatic transaminases, hemochromatotic arthropathy, hepatic fibrosis, or cirrhosis [
         <a href="#rid121">
          121
         </a>
         ]. The average age at the time of testing was 41 years for men and 44 years for women, and the risk for disease complications was higher in men over age 40 and women over age 50. Data such as these provide the rationale for evaluating all first-degree relatives of individuals with HH, typically after they reach adulthood. (See
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Testing and counseling first-degree relatives'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Age and sex
         </strong>
         – Males and postmenopausal women have a higher risk of developing iron overload because they do not lose iron during monthly menstrual cycles or pregnancy. The risk of HH increases with age due to progressive accumulation of iron over time. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Typical presentations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alcohol use or other comorbidities
         </strong>
         – Alcohol intake is often a consideration in individuals with HH-associated liver disease and appears to increase the risk of progression to cirrhosis. In one study involving C282Y/H63D compound heterozygotes, complications of iron overload only developed in those with excess alcohol use or another comorbidity such as diabetes or hepatic steatosis [
         <a href="#rid122">
          122
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Limiting alcohol'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic modifiers
         </strong>
         – Several iron regulatory genes have been identified that may modify risk. (See
         <a class="local">
          'Genetic modifiers of HFE'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other genetic conditions
         </strong>
         – Beta-thalassemia may cause ineffective erythropoiesis, which in turn increases intestinal iron absorption. A small study found that compared with controls with the same
         <em>
          HFE
         </em>
         genotype, individuals who were also carriers of beta-thalassemia
         <strong>
          trait
         </strong>
         developed iron overload at an earlier age and had a higher degree of iron overload and related complications (heart failure, hypogonadism, liver disease) [
         <a href="#rid123">
          123
         </a>
         ]. This might be related to the well-known mechanism of hepcidin inhibition by erythroferrone that is increased in beta-thalassemia [
         <a href="#rid124">
          124
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7116.html" rel="external">
          "Diagnosis of thalassemia (adults and children)", section on 'Iron overload'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H781998711">
         <span class="h2">
          Sequence of testing in individuals with iron overload
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of HH generally requires clinical iron overload as well as a relevant
         <em>
          HFE
         </em>
         genotype. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Diagnostic criteria'
         </a>
         .)
        </p>
        <p>
         Thus, testing for
         <em>
          HFE
         </em>
         mutations is appropriate in individuals with increased TSAT, increased serum ferritin, or other evidence of iron overload. This is especially true for those who do not have another cause of iron overload such as beta-thalassemia or transfusional iron overload, but it may also be appropriate in individuals who do have other causes of iron overload, those with other causes of liver disease such as porphyria cutanea tarda, and/or those with unexplained increases in hepatic transaminases.
        </p>
        <p>
         Typically, initial
         <em>
          HFE
         </em>
         genotyping panels test for the C282Y and H63D variants. Homozygosity for C282Y or compound heterozygosity for these two variants accounts for the vast majority of individuals with HH.
        </p>
        <p>
         For individuals with negative initial
         <em>
          HFE
         </em>
         genotyping, there are several options for subsequent evaluations. Regardless of the genotype, clinically significant iron overload should be treated (ie, the absence of an
         <em>
          HFE
         </em>
         mutation is not a reason to withhold treatment). (See
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Iron removal'
         </a>
         .)
        </p>
        <p>
         Options for further testing include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For an individual with a known familial genotype that includes variants other than C282Y and H63D, it may be reasonable to test for the familial variant(s) alone. This is especially true if there are first-degree relatives for whom this genotyping information may help guide management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who have developed iron overload at a younger age (eg, before age 40 in men or before menopause in women) or those from non-European backgrounds, it may be reasonable to test for less common
         <em>
          HFE
         </em>
         variants and variants in other genes (see
         <a class="local">
          'Non-HFE hemochromatosis'
         </a>
         above). This is especially true if genotyping information would be helpful for first-degree relatives. Sequential testing versus the use of a gene panel is individualized based on patient features and available testing resources. Testing for specific variants in the relevant gene(s) versus gene sequencing using a next generation sequencing (NGS) approach is also individualized based on available resources [
         <a href="#rid125">
          125,126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For individuals who do not wish to pursue further testing, it is reasonable to treat for non-
         <em>
          HFE
         </em>
         iron overload without documenting the underlying genotype. This is especially true for those in whom additional testing would incur additional costs and burdens without additional benefit. (See
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Iron removal'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those with a high ferritin without evidence of iron overload (ie, no elevation in TSAT and/or no evidence of iron deposition on magnetic resonance imaging [MRI] or tissue biopsy), evaluation for other conditions that increase serum ferritin (eg, chronic inflammatory conditions, liver injury) may be appropriate. (See
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload", section on 'Other causes of high ferritin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3016567140">
         <span class="h2">
          Testing of first-degree relatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         First-degree relatives of individuals with HH should be tested for the familial mutation(s) and for iron overload (eg, with iron studies). Important considerations, such as delaying testing until adulthood, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Asymptomatic first-degree relatives'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Testing and counseling first-degree relatives'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2963207925">
         <span class="h1">
          ROLE OF POPULATION SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is general agreement that routine population screening for hereditary hemochromatosis (HH) using genetic testing is not cost-effective, and we suggest routine genetic testing not be performed in average-risk individuals in the general population (those who lack evidence of iron overload and have a negative family history for
         <em>
          HFE
         </em>
         -related HH). This is consistent with most guidelines and consensus documents, which advise against unselected population screening for mutations in
         <em>
          HFE
         </em>
         or other hemochromatosis genes [
         <a href="#rid127">
          127,128
         </a>
         ].
        </p>
        <p>
         Additional reasons cited for avoiding routine population screening have included the unclear prevalence of clinically significant disease, the lack of demonstrated benefits to screening that outweigh risks and costs, possible reluctance of insurance carriers to pay the costs of phlebotomy in asymptomatic individuals, possible genetic discrimination (documented in some reports), and unnecessary interventions and/or anxiety, and difficulty communicating results to large numbers of individuals [
         <a href="#rid129">
          129-134
         </a>
         ]. Further, no studies have established whether population screening impacts patient-important outcomes such as liver disease or heart disease from HH.
        </p>
        <p>
         The
         <em>
          HFE
         </em>
         C282Y variant has a relatively high prevalence, and, in contrast to the general population, screening may be reasonable for certain populations who are at higher risk for developing iron overload (eg, men and postmenopausal women) [
         <a href="#rid135">
          135
         </a>
         ]. If high-risk individuals are screened, phenotypic testing with iron studies (ferritin and transferrin saturation [TSAT]) rather than
         <em>
          HFE
         </em>
         genotyping may be the best screening test. Cost-effectiveness studies have found the expense of screening for HH using iron studies to be reasonable considering the number of individuals who would not otherwise have been identified [
         <a href="#rid136">
          136,137
         </a>
         ].
        </p>
        <p>
         <em>
          HFE
         </em>
         testing is often appropriate for individuals with iron overload and almost always appropriate for at-risk relatives (eg, first degree relatives) of an individual with HH. In these cases, genetic testing can facilitate identification of other affected family members, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'HFE genetic testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Testing and counseling first-degree relatives'
         </a>
         .)
        </p>
        <p>
         Some individuals may present with results of
         <em>
          HFE
         </em>
         genetic testing even without an indication for screening, and they may ask about whether additional testing or interventions are needed. If
         <em>
          HFE
         </em>
         testing reveals an HH-associated genotype, a family history should be elicited and iron studies should be performed, and the
         <em>
          HFE
         </em>
         genotype should be interpreted in context with this other information. A finding of one or more
         <em>
          HFE
         </em>
         mutations by itself is not sufficient for the diagnosis of HH; the genotype only confers a susceptibility to iron overload, and many individuals with
         <em>
          HFE
         </em>
         mutations will never manifest the disorder [
         <a href="#rid138">
          138
         </a>
         ]. (See
         <a class="local">
          'Likelihood of developing iron overload'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3876874164">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116616.html" rel="external">
          "Society guideline links: Hemochromatosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H974007">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15875.html" rel="external">
          "Patient education: Hemochromatosis (The Basics)"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4573.html" rel="external">
          "Patient education: Hereditary hemochromatosis (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3358599">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           HFE
          </em>
         </strong>
         <strong>
          gene
         </strong>
         – The
         <em>
          HFE
         </em>
         gene encodes a protein that regulates hepcidin production by hepatocytes. Pathogenic variants in
         <em>
          HFE
         </em>
         , primarily C282Y, can lead to increased iron absorption that sometimes causes tissue iron overload. (See
         <a class="local">
          'HFE gene function'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7105.html" rel="external">
          "Regulation of iron balance"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hereditary hemochromatosis
         </strong>
         – Hereditary hemochromatosis (HH) is an autosomal recessive disorder with variable penetrance. Homozygosity for
         <em>
          HFE
         </em>
         C282Y is generally required for clinical iron overload, but many of these individuals will never develop HH (
         <a class="graphic graphic_table graphicRef126542" href="/z/d/graphic/126542.html" rel="external">
          table 2
         </a>
         ). Rarely, compound heterozygosity with the H63D variant (C282Y/H63D) or
         <em>
          HFE
         </em>
         gene deletion may be associated with iron overload, usually mild. In such cases, secondary causes of iron overload and liver disease (excess alcohol, hepatitis C virus, nonalcoholic fatty liver disease) should be sought and treated. Heterozygosity for
         <em>
          HFE
         </em>
         C282Y generally produces an unaffected carrier state with similar risk of iron overload as the general population. In some heterozygotes, concomitant liver disease may cause abnormal iron studies. (See
         <a class="local">
          'HFE variants in hereditary hemochromatosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other iron regulatory genes
         </strong>
         – Rarely, iron overload can be caused by variants in other iron regulatory genes, referred to as non-
         <em>
          HFE
         </em>
         hemochromatosis. Juvenile hemochromatosis, which typically presents in childhood, adolescence, or young adulthood, may be due to mutations in
         <em>
          HJV
         </em>
         (encodes hemojuvelin) or
         <em>
          HAMP
         </em>
         (encodes hepcidin). Other genes, inheritance patterns, and clinical features are discussed above. (See
         <a class="local">
          'Non-HFE hemochromatosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of iron overload
         </strong>
         – The risk of iron overload in an
         <em>
          HFE
         </em>
         C282Y homozygote (C282Y/C282Y) is challenging to estimate. Population studies have reported risks from 1 percent in females to 28 percent in males (
         <a class="graphic graphic_table graphicRef126542" href="/z/d/graphic/126542.html" rel="external">
          table 2
         </a>
         ). Positive family history, male sex, older age, and excess alcohol use can all increase the likelihood of iron overload. (See
         <a class="local">
          'Likelihood of developing iron overload'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of genetic testing
         </strong>
         – Individuals with iron overload should be tested for
         <em>
          HFE
         </em>
         C282Y and H63D or for a familial mutation (if known). Other testing may be appropriate for individuals who present at a younger than average age (before age 40 in males or before menopause in females) or those from non-European backgrounds, especially if genotype information would be helpful for first-degree relatives. For individuals who do not wish to pursue testing, it is reasonable to treat iron overload without documenting the genotype, especially if testing would incur significant costs and burdens without altering management. (See
         <a class="local">
          'Sequence of testing in individuals with iron overload'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First-degree relatives
         </strong>
         – First-degree relatives of individuals with HH should be tested, typically with iron studies as well as genotyping. This is generally deferred to adulthood. An exception is a sibling of an individual with juvenile hemochromatosis, who may require testing at a younger age. (See
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis", section on 'Asymptomatic first-degree relatives'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis", section on 'Testing and counseling first-degree relatives'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Population screening
         </strong>
         – For asymptomatic individuals with a negative family history and no iron overload, we suggest not routinely screening for HH (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Screening may be reasonable in selected populations, especially White males of northern European ancestry. Iron studies (ferritin and transferrin saturation [TSAT]) rather than
         <em>
          HFE
         </em>
         genotyping may be the best screening test. (See
         <a class="local">
          'Role of population screening'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of a high ferritin and other causes of iron overload are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload", section on 'Other causes of high ferritin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7167.html" rel="external">
          "Clinical manifestations and diagnosis of hereditary hemochromatosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of HH
         </strong>
         – Management and prognosis of HH and testing of first-degree relatives are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7136.html" rel="external">
          "Management and prognosis of hereditary hemochromatosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2066612676">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
        <p>
         The UpToDate editorial staff also acknowledges the extensive contributions of Bruce R Bacon, MD, and William C Mentzer, MD, to earlier versions of this and many other topic reviews.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Bacon BR, Fleming RE. Hemochromatosis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th ed, Feldman M, Friedman L, Brandt L (Eds), Elsevier, 2020. p.1172.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med 2012; 366:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 1976; 17:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton JC, Edwards CQ, Acton RT. HFE gene: Structure, function, mutations, and associated iron abnormalities. Gene 2015; 574:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercier B, Mura C, Ferec C. Putting a hold on 'HLA-H'. Nat Genet 1997; 15:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ajioka RS, Jorde LB, Gruen JR, et al. Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. Am J Hum Genet 1997; 60:1439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams PC. Hemochromatosis: Ancient to the Future. Clin Liver Dis (Hoboken) 2020; 16:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jouanolle AM, Gandon G, Jézéquel P, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jazwinska EC, Cullen LM, Busfield F, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carella M, D'Ambrosio L, Totaro A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 1997; 60:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen P, Carpinteiro S, Fischer R, et al. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany. Br J Haematol 1998; 103:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebrón JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothenberg BE, Voland JR. beta2 knockout mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci U S A 1996; 93:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos M, Schilham MW, Rademakers LH, et al. Defective iron homeostasis in beta 2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J Exp Med 1996; 184:1975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 1997; 272:14025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waheed A, Parkkila S, Zhou XY, et al. Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A 1997; 94:12384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feder JN, Penny DM, Irrinki A, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 1998; 95:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebrón JA, West AP Jr, Bjorkman PJ. The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor. J Mol Biol 1999; 294:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu XG, Wang Y, Wu Q, et al. HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression. Blood 2014; 124:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dijk BA, Laarakkers CM, Klaver SM, et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol 2008; 142:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chua AC, Herbison CE, Drake SF, et al. The role of Hfe in transferrin-bound iron uptake by hepatocytes. Hepatology 2008; 47:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardou-Jacquet E, Philip J, Lorho R, et al. Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis. Hepatology 2014; 59:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vujic Spasic M, Kiss J, Herrmann T, et al. Physiologic systemic iron metabolism in mice deficient for duodenal Hfe. Blood 2007; 109:4511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vujić Spasić M, Kiss J, Herrmann T, et al. Hfe acts in hepatocytes to prevent hemochromatosis. Cell Metab 2008; 7:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306:2090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkkila S, Waheed A, Britton RS, et al. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U S A 1997; 94:13198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reuben A, Chung JW, Lapointe R, Santos MM. The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system. Immun Inflamm Dis 2017; 5:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girelli D, Marchi G, Busti F, Vianello A. Iron metabolism in infections: Focus on COVID-19. Semin Hematol 2021; 58:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girelli D, Busti F, Brissot P, et al. Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood 2022; 139:3018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kowdley KV, Brown KE, Ahn J, Sundaram V. ACG Clinical Guideline: Hereditary Hemochromatosis. Am J Gastroenterol 2019; 114:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mura C, Raguenes O, Férec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999; 93:2502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010; 139:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352:1769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Dijk BA, Kemna EH, Tjalsma H, et al. Effect of the new HJV-L165X mutation on penetrance of HFE. Blood 2007; 109:5525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DF, Dooley JS, Walker AP. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology 1999; 116:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piperno A, Arosio C, Fossati L, et al. Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis. Gastroenterology 2000; 119:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cullen LM, Gao X, Easteal S, Jazwinska EC. The hemochromatosis 845 G--&gt;A and 187 C--&gt;G mutations: prevalence in non-Caucasian populations. Am J Hum Genet 1998; 62:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigues P, Lopes C, Mascarenhas C, et al. Comparative study between Hfe-/- and beta2m-/- mice: progression with age of iron status and liver pathology. Int J Exp Pathol 2006; 87:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurrin LC, Bertalli NA, Dalton GW, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009; 50:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamdi-Rozé H, Beaumont-Epinette MP, Ben Ali Z, et al. Rare HFE variants are the most frequent cause of hemochromatosis in non-c282y homozygous patients with hemochromatosis. Am J Hematol 2016; 91:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Gac G, Gourlaouen I, Ronsin C, et al. Homozygous deletion of HFE produces a phenotype similar to the HFE p.C282Y/p.C282Y genotype. Blood 2008; 112:5238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelucchi S, Mariani R, Bertola F, et al. Homozygous deletion of HFE: the Sardinian hemochromatosis? Blood 2009; 113:3886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Gac G, Congiu R, Gourlaouen I, et al. Homozygous deletion of HFE is the common cause of hemochromatosis in Sardinia. Haematologica 2010; 95:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ka C, Chen JM, Gourlaouen I, et al. Characterization of the second HFE gross deletion highlights the potential importance of Alu-mediated recombination in haemochromatosis. Br J Haematol 2015; 168:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radio FC, Majore S, Aurizi C, et al. Hereditary hemochromatosis type 1 phenotype modifiers in Italian patients. The controversial role of variants in HAMP, BMP2, FTL and SLC40A1 genes. Blood Cells Mol Dis 2015; 55:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borgel A, Lamoril J, Tchernitchko D. Mutations and polymorphisms associated with iron overload in a series of 91 non-HFE haemochromatosis patients. Clin Res Hepatol Gastroenterol 2020; 44:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milet J, Le Gac G, Scotet V, et al. A common SNP near BMP2 is associated with severity of the iron burden in HFE p.C282Y homozygous patients: a follow-up study. Blood Cells Mol Dis 2010; 44:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silvestri L, Nai A, Dulja A, Pagani A. Hepcidin and the BMP-SMAD pathway: An unexpected liaison. Vitam Horm 2019; 110:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daher R, Kannengiesser C, Houamel D, et al. Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans. Gastroenterology 2016; 150:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald CJ, Rishi G, Wallace DF, Subramaniam VN. Genetic Variants in the BMP6 Pro-Peptide May Not Cause Iron Loading and Should Be Interpreted With Caution. Gastroenterology 2016; 151:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piubelli C, Castagna A, Marchi G, et al. Identification of new BMP6 pro-peptide mutations in patients with iron overload. Am J Hematol 2017; 92:562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaren CE, Emond MJ, Subramaniam VN, et al. Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload. Hepatology 2015; 62:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stickel F, Buch S, Zoller H, et al. Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Hum Mol Genet 2014; 23:3883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003; 12:2241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacolot S, Le Gac G, Scotet V, et al. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 103:2835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Gac G, Scotet V, Ka C, et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet 2004; 13:1913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilling LC, Atkins JL, Melzer D. Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: Associations in a large community cohort. Hepatology 2022; 76:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandhu K, Flintoff K, Chatfield MD, et al. Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease. Blood 2018; 132:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zoller H, Cox TM. Hemochromatosis: genetic testing and clinical practice. Clin Gastroenterol Hepatol 2005; 3:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camaschella C, Poggiali E. Towards explaining "unexplained hyperferritinemia". Haematologica 2009; 94:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011; 117:4425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mantilla-Hernández JC, Amaya-Mujica J. Juvenile hemochromatosis with multi-organ involvement diagnosed at autopsy. Rev Esp Patol 2019; 52:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roetto A, Totaro A, Cazzola M, et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999; 64:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanzara C, Roetto A, Daraio F, et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 2004; 103:4317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004; 36:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood 2004; 103:4669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camaschella C, Roetto A, Cicilano M, et al. Juvenile and adult hemochromatosis are distinct genetic disorders. Eur J Hum Genet 1997; 5:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly AL, Rhodes DA, Roland JM, et al. Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. QJM 1998; 91:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camaschella C, Fargion S, Sampietro M, et al. Inherited HFE-unrelated hemochromatosis in Italian families. Hepatology 1999; 29:1563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartella I, Tavecchia GA, Quattrocchi G, et al. A heart of iron: juvenile haemochromatosis presents with cardiac failure. Lancet 2022; 400:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin L, Goldberg YP, Ganz T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 2005; 106:2884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006; 38:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Babitt JL, Huang FW, Xia Y, et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 2007; 117:1933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xia Y, Babitt JL, Sidis Y, et al. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008; 111:5195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roetto A, Papanikolaou G, Politou M, et al. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 2003; 33:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matthes T, Aguilar-Martinez P, Pizzi-Bosman L, et al. Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'-UTR of the HAMP gene. Blood 2004; 104:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hattori A, Tomosugi N, Tatsumi Y, et al. Identification of a novel mutation in the HAMP gene that causes non-detectable hepcidin molecules in a Japanese male patient with juvenile hemochromatosis. Blood Cells Mol Dis 2012; 48:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lok CY, Merryweather-Clarke AT, Viprakasit V, et al. Iron overload in the Asian community. Blood 2009; 114:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roetto A, Totaro A, Piperno A, et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 97:2555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girelli D, Bozzini C, Roetto A, et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002; 122:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattman A, Huntsman D, Lockitch G, et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 2002; 100:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Gac G, Mons F, Jacolot S, et al. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br J Haematol 2004; 125:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bardou-Jacquet E, Cunat S, Beaumont-Epinette MP, et al. Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations. Br J Haematol 2013; 162:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietrangelo A, Caleffi A, Henrion J, et al. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. Gastroenterology 2005; 128:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. Int J Hematol 2018; 107:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleven MD, Jue S, Enns CA. Transferrin Receptors TfR1 and TfR2 Bind Transferrin through Differing Mechanisms. Biochemistry 2018; 57:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girelli D, Trombini P, Busti F, et al. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 2011; 96:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietrangelo A. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica 2017; 102:1972.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Y, Du Y, Liu G, et al. Identification of novel mutations in HFE, HFE2, TfR2, and SLC40A1 genes in Chinese patients affected by hereditary hemochromatosis. Int J Hematol 2017; 105:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivers CA, Barton JC, Gordeuk VR, et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis 2007; 38:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace DF, Pedersen P, Dixon JL, et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devalia V, Carter K, Walker AP, et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002; 100:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roetto A, Merryweather-Clarke AT, Daraio F, et al. A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4. Blood 2002; 100:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremonesi L, Forni GL, Soriani N, et al. Genetic and clinical heterogeneity of ferroportin disease. Br J Haematol 2005; 131:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths WJ, Mayr R, McFarlane I, et al. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation. Hepatology 2010; 51:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandes A, Preza GC, Phung Y, et al. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood 2009; 114:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sham RL, Phatak PD, Nemeth E, Ganz T. Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation. Blood 2009; 114:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Létocart E, Le Gac G, Majore S, et al. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. Br J Haematol 2009; 147:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aschemeyer S, Qiao B, Stefanova D, et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. Blood 2018; 131:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cazzola M, Cremonesi L, Papaioannou M, et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). Br J Haematol 2002; 119:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi EK, Seo YA. Influence of Ferroportin Disease Mutations on Manganese Accumulation and Toxicity (P24-060-19). Curr Dev Nutr 2019; 3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muckenthaler L, Marques O, Colucci S, et al. Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction. Blood 2022; 139:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 2003; 101:3347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen KJ, Gurrin LC, Constantine CC, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacon BR, Britton RS. Clinical penetrance of hereditary hemochromatosis. N Engl J Med 2008; 358:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atkins JL, Pilling LC, Masoli JAH, et al. Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy. JAMA 2020; 324:2048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G--&gt; A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen RV, Tybjaerg-Hansen A, Appleyard M, et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 2004; 103:2914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2006; 4:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powell LW, Dixon JL, Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 2006; 166:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming RE, Holden CC, Tomatsu S, et al. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 2001; 98:2707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelucchi S, Mariani R, Calza S, et al. CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients. Haematologica 2012; 97:1818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Constantine CC, Anderson GJ, Vulpe CD, et al. A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis. Br J Haematol 2009; 147:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000; 343:1529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh A, Dixon JL, Ramm GA, et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol Hepatol 2006; 4:1403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piperno A, Mariani R, Arosio C, et al. Haemochromatosis in patients with beta-thalassaemia trait. Br J Haematol 2000; 111:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganz T, Jung G, Naeim A, et al. Immunoassay for human serum erythroferrone. Blood 2017; 130:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald CJ, Ostini L, Wallace DF, et al. Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders. J Hepatol 2015; 63:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badar S, Busti F, Ferrarini A, et al. Identification of novel mutations in hemochromatosis genes by targeted next generation sequencing in Italian patients with unexplained iron overload. Am J Hematol 2016; 91:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 1998; 280:172.
          </a>
         </li>
         <li class="breakAll">
          https://www.choosingwisely.org/clinician-lists/american-college-medical-genetics-genomics-hfe-genetic-testing/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitlock EP, Garlitz BA, Harris EL, et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2006; 145:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitt B, Golub RM, Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 2005; 143:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           U.S. Preventive Services Task Force. Screening for hemochromatosis: recommendation statement. Ann Intern Med 2006; 145:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaheen NJ, Lawrence LB, Bacon BR, et al. Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage. Am J Gastroenterol 2003; 98:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Power TE, Adams PC. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test 2001; 5:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison HF, Harrison BW, Walker AP, et al. Screening for hemochromatosis and iron overload: satisfaction with results notification and understanding of mailed results in unaffected participants of the HEIRS study. Genet Test 2008; 12:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phatak PD, Bonkovsky HL, Kowdley KV. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008; 149:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balan V, Baldus W, Fairbanks V, et al. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology 1994; 107:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol 1999; 94:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brissot P, Pietrangelo A, Adams PC, et al. Haemochromatosis. Nat Rev Dis Primers 2018; 4:18016.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7067 Version 46.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Bacon BR, Fleming RE. Hemochromatosis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th ed, Feldman M, Friedman L, Brandt L (Eds), Elsevier, 2020. p.1172.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22276824" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Iron overload in human disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8696333" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1278715" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26456104" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : HFE gene: Structure, function, mutations, and associated iron abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9054932" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Putting a hold on 'HLA-H'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9199565" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33042529" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Hemochromatosis: Ancient to the Future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8896550" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Haemochromatosis and HLA-H.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8896549" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Haemochromatosis and HLA-H.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8931958" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Mutation analysis in hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9106528" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mutation analysis of the HLA-H gene in Italian hemochromatosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9858243" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9546397" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8643666" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : beta2 knockout mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8920884" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Defective iron homeostasis in beta 2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9162021" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9356458" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9465039" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10556042" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24904118" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : HFE interacts with the BMP type I receptor ALK3 to regulate hepcidin expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18557745" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18393371" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The role of Hfe in transferrin-bound iron uptake by hepatocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23775519" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17264297" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Physiologic systemic iron metabolism in mice deficient for duodenal Hfe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18249176" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hfe acts in hepatocytes to prevent hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15514116" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9371823" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28474781" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34389110" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Iron metabolism in infections: Focus on COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34601591" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hemochromatosis classification: update and recommendations by the BIOIRON Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31335359" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : ACG Clinical Guideline: Hereditary Hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10194428" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11479183" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20542038" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15858186" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hemochromatosis and iron-overload screening in a racially diverse population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10471457" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A population-based study of the clinical expression of the hemochromatosis gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17554070" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effect of the new HJV-L165X mutation on penetrance of HFE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10348824" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10930379" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Two novel nonsense mutations of HFE gene in five unrelated italian patients with hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9585606" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The hemochromatosis 845 G--&gt;A and 187 C--&gt;G mutations: prevalence in non-Caucasian populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16875497" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Comparative study between Hfe-/- and beta2m-/- mice: progression with age of iron status and liver pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19554541" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27518069" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Rare HFE variants are the most frequent cause of hemochromatosis in non-c282y homozygous patients with hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18809761" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Homozygous deletion of HFE produces a phenotype similar to the HFE p.C282Y/p.C282Y genotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19372266" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Homozygous deletion of HFE: the Sardinian hemochromatosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20007136" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Homozygous deletion of HFE is the common cause of hemochromatosis in Sardinia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Characterization of the second HFE gross deletion highlights the potential importance of Alu-mediated recombination in haemochromatosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25976471" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Hereditary hemochromatosis type 1 phenotype modifiers in Italian patients. The controversial role of variants in HAMP, BMP2, FTL and SLC40A1 genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31640930" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Mutations and polymorphisms associated with iron overload in a series of 91 non-HFE haemochromatosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19879168" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A common SNP near BMP2 is associated with severity of the iron burden in HFE p.C282Y homozygous patients: a follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30798817" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Hepcidin and the BMP-SMAD pathway: An unexpected liaison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26582087" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hepcidin Synthesis and Moderate Iron Overload in Humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27591424" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Genetic Variants in the BMP6 Pro-Peptide May Not Cause Iron Loading and Should Be Interpreted With Caution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28335084" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Identification of new BMP6 pro-peptide mutations in patients with iron overload.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25605615" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24556216" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915468" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14670915" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15254010" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35567766" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Genetic modifiers of penetrance to liver endpoints in HFE hemochromatosis: Associations in a large community cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29743178" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16234038" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Hemochromatosis: genetic testing and clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19252171" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Towards explaining "unexplained hyperferritinemia".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21346250" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hepcidin and iron regulation, 10 years later.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30583831" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Juvenile hemochromatosis with multi-organ involvement diagnosed at autopsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10205270" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Juvenile hemochromatosis locus maps to chromosome 1q.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14982873" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14647275" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14982867" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9450181" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Juvenile and adult hemochromatosis are distinct genetic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10024915" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10216143" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Inherited HFE-unrelated hemochromatosis in Italian families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35988570" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A heart of iron: juvenile haemochromatosis presents with cardiac failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15998830" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16604073" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17607365" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18326817" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12469120" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15198949" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'-UTR of the HAMP gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22297252" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Identification of a novel mutation in the HAMP gene that causes non-detectable hepcidin molecules in a Japanese male patient with juvenile hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19342478" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Iron overload in the Asian community.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11313241" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : New mutations inactivating transferrin receptor 2 in hemochromatosis type 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11984516" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12130528" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15147384" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23600741" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15685557" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29134618" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29388418" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Transferrin Receptors TfR1 and TfR2 Bind Transferrin through Differing Mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21173098" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29101207" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Ferroportin disease: pathogenesis, diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27896572" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Identification of novel mutations in HFE, HFE2, TfR2, and SLC40A1 genes in Chinese patients affected by hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17276706" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11431687" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518736" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12091366" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12091367" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12123233" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A valine deletion of ferroportin 1: a common mutation in hemochromastosis type 4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10471458" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16351644" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Genetic and clinical heterogeneity of ferroportin disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19937651" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19383972" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : The molecular basis of hepcidin-resistant hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19589941" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19709084" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29237594" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12406098" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31224069" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Influence of Ferroportin Disease Mutations on Manganese Accumulation and Toxicity (P24-060-19).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34875027" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12707220" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18199861" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Iron-overload-related disease in HFE hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18199868" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Clinical penetrance of hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33231665" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11812557" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Penetrance of 845G--&gt;A (C282Y) HFE hereditary haemochromatosis mutation in the USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15070663" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Hemochromatosis mutations in the general population: iron overload progression rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16797244" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Liver diseases in the hemochromatosis and iron overload screening study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16476869" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Screening for hemochromatosis in asymptomatic subjects with or without a family history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11226304" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22773607" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19673882" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : A novel association between a SNP in CYBRD1 and serum ferritin levels in a cohort study of HFE hereditary haemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11087882" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Disease-related conditions in relatives of patients with hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16979952" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11122155" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Haemochromatosis in patients with beta-thalassaemia trait.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28739636" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Immunoassay for human serum erythroferrone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26151776" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26799139" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Identification of novel mutations in hemochromatosis genes by targeted next generation sequencing in Italian patients with unexplained iron overload.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9669792" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Hereditary hemochromatosis: gene discovery and its implications for population-based screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9669792" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Hereditary hemochromatosis: gene discovery and its implications for population-based screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16880463" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16204165" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16880462" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Screening for hemochromatosis: recommendation statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12809845" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11551095" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Psychosocial impact of C282Y mutation testing for hemochromatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18939938" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Screening for hemochromatosis and iron overload: satisfaction with results notification and understanding of mailed results in unaffected participants of the HEIRS study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18711158" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Hereditary hemochromatosis: time for targeted screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8039622" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10364030" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29620054" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Haemochromatosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
